GTx to Host Key Opinion Leader Luncheon on the Topic of Stress Urinary Incontinence on September 28th in New York City
September 21 2017 - 4:05PM
Business Wire
GTx, Inc. (Nasdaq: GTXI) today announced that it will be hosting
and simultaneously webcasting a Key Opinion Leader (KOL) luncheon
meeting on the topic of Stress Urinary Incontinence (SUI) on
Thursday, September 28th in New York City beginning at 12:00 p.m.
EDT.
The meeting will feature presentations by key opinion leaders
Roger Dmochowski, MD (Vanderbilt University), William Evans, PhD
(Duke University), and Diane Newman, DNP, FAAN (University of
Pennsylvania) who will discuss the current treatment landscape and
unmet medical need for patients with SUI. The KOLs will be
available to answer questions at the conclusion of the event.
GTx's management team will also provide an overview of the
Company’s ongoing clinical development program with enobosarm
(GTx-024), a novel small molecule candidate to treat stress urinary
incontinence. Enobosarm is an orally-administered selective
androgen receptor modulator (SARM), which is currently in Phase 2
clinical trial development for the treatment of SUI in
postmenopausal women. The company released top-line clinical
results from its ongoing Phase 2 proof-of-concept clinical trial of
enobosarm to treat SUI on September 13, 2017.
The in-person luncheon meeting is intended for institutional
investors, sell-side analysts, investment bankers, and business
development professionals only. Please RSVP in advance if you plan
to attend in person, as space is limited. A simultaneous webcast of
the luncheon meeting will be accessible from the GTx website at
http://www.gtxinc.com. An archived replay of the presentation will
be available on GTx’s website. Please connect to the website prior
to the start of the luncheon meeting to ensure adequate time for
any software downloads that may be necessary to listen to the
webcast.
About GTxGTx, Inc., headquartered in Memphis, Tennessee,
is a biopharmaceutical company dedicated to the discovery,
development and commercialization of small molecules for the
treatment of muscle-related diseases and other serious medical
conditions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921006067/en/
Investors:GTx, Inc.Lauren Crosby,
901-271-8622lcrosby@gtxinc.comorMedia:Red House ConsultingDenise
Powell, 510-703-9491denise@redhousecomms.com
Gtx, Inc. (NASDAQ:GTXI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Gtx, Inc. (NASDAQ:GTXI)
Historical Stock Chart
From Sep 2023 to Sep 2024
